secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fortress Biotech, Inc. (FBIO)
CIK:        0001429260
Form:       8-K
Filed at:   2026-03-31T23:59:59+00:00
Accession:  0001104659-26-037749
Event type: other_material
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fortress Biotech reports 2025 results; ZYCUBO approved, PRV sold for $205M
--------------------------------------------------------------------------

- ZYCUBO FDA-approved for Menkes disease; Cyprium sold PRV for $205M gross, with potential $128M in sales milestones.
- Checkpoint acquired by Sun Pharma; Fortress received ~$28M upfront, up to $4.8M CVR, and 2.5% royalty on UNLOXCYT.
- Consolidated net loss attributable to common stockholders improved to $(1.9)M ($(0.07)/share) vs $(55.9)M ($(2.69)/share) in 2024.
- Revenue rose to $63.3M in 2025 from $57.7M in 2024, driven by Journey Medical's Emrosi and dermatology portfolio.
- Prepaid Oaktree loan to $15.0M outstanding; cash at $79.4M as of year-end 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1429260/000110465926037749/0001104659-26-037749-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1429260/000110465926037749/fbio-20260331x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-037749

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer